Satsuma Pharmaceuticals I... (STSA)
Satsuma Pharmaceuticals Statistics
Share Statistics
Satsuma Pharmaceuticals has 33.15M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 33.15M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 15.2M |
| Failed to Deliver (FTD) Shares | 238 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.42 and the forward PE ratio is null. Satsuma Pharmaceuticals's PEG ratio is -0.02.
| PE Ratio | -0.42 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | -0.14 |
| P/FCF Ratio | -0.55 |
| PEG Ratio | -0.02 |
Enterprise Valuation
Satsuma Pharmaceuticals has an Enterprise Value (EV) of 12.53M.
| EV / Sales | 0 |
| EV / EBITDA | -0.21 |
| EV / EBIT | -0.24 |
| EV / FCF | -0.24 |
Financial Position
The company has a current ratio of 6.75, with a Debt / Equity ratio of 0.
| Current Ratio | 6.75 |
| Quick Ratio | 6.75 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | -5457.46 |
Financial Efficiency
Return on Equity is 32.66% and Return on Invested Capital is 33.09%.
| Return on Equity | 32.66% |
| Return on Assets | -125.89% |
| Return on Invested Capital | 33.09% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2.77M |
| Employee Count | 25 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -892K |
| Effective Tax Rate | 1.27% |
Stock Price Statistics
The stock price has increased by 0% in the last 52 weeks. The beta is 0.1, so Satsuma Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.1 |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 0.97 |
| 200-Day Moving Average | 2.38 |
| Relative Strength Index (RSI) | 60.82 |
| Average Volume (20 Days) | 1.11M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -70.95M |
| Net Income | -69.16M |
| EBITDA | -58.31M |
| EBIT | -70.04M |
| Earnings Per Share (EPS) | -2.16 |
Balance Sheet
The company has 16.43M in cash and 138K in debt, giving a net cash position of 16.29M.
| Cash & Cash Equivalents | 16.43M |
| Total Debt | 138K |
| Net Cash | 16.29M |
| Retained Earnings | -211.79M |
| Total Assets | 43.48M |
| Working Capital | 37.54M |
Cash Flow
In the last 12 months, operating cash flow was -51.52M and capital expenditures -472K, giving a free cash flow of -51.99M.
| Operating Cash Flow | -51.52M |
| Capital Expenditures | -472K |
| Free Cash Flow | -51.99M |
| FCF Per Share | -1.62 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
STSA pays an annual dividend of $1.35, which amounts to a dividend yield of 6.8%.
| Dividend Per Share | $1.35 |
| Dividend Yield | 6.8% |
| Dividend Growth (YoY) | 0% |
| Payout Ratio | -67.84% |
| Earnings Yield | -239.96% |
| FCF Yield | -180.37% |
Analyst Forecast
Currently there are no analyst rating for STSA.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -7.38 |
| Piotroski F-Score | 2 |